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Introduction
An inpatient is usually defined as a patient who is
admitted to a hospital or clinic for treatment that
requires at least one overnight stay. However, since 1
August 2006, and for reimbursement purposes, under
Portuguese law the length of stay must be longer than
24 hours to be considered a valid inpatient stay.
The Portuguese National Health System hospitals are
financed through two different schemes. For patients
with a third party responsible for health expenditure,
the hospital charges a fixed price by DRG for each inpa-
tient stay, and for some outpatient visits such as che-
motherapy, ambulatory surgery, and dialysis, among
others.
For patients covered solely by the National Health
System, hospitals are financed through an annual agree-
ment. Under this agreement, there is a single fixed price
for inpatient stays as well as those outpatient visits
which have a DRG associated. Each type of production
is valued by applying that price, adjusted by the case-
mix index for that type, to the amount of equivalent
inpatient stays (adjusted to the medium length of stay
outside the considered normality limits) or outpatient
visits.
Stays under 24 hours, since they are registered as
inpatient stays, are not eligible for inpatient reimburse-
ment under either scheme. In addition, they are also not
considered proper outpatient visits, and are not paid as
such to the hospital. Even so, the hospital incurs costs
with these patients, often including surgical procedures
or other costly treatments. Our aim is to show how
invalid inpatient stays affect both the hospital’sb u d g e t
and funding.
Methods
We identified the invalid inpatient stays, both for medi-
cal and surgical DRG, registered in 2008 in all public
hospitals under the north region health administration
(16 hospitals). We then proceeded to calculate their
weight on the total number of inpatients for each hospi-
tal, the value the hospital would receive if those stays
were registered as outpatient visits (both for all patients
h a v i n gat h i r dp a r t yf i n a n c i a lr e s p o n s i b l ea n df o ra l l
patients being covered by the National Health Service),
and the impact of this latter value, as a percentage, on
the hospital outpatient budget of the annual agreement.
Results
Overall we identified 2,907 stays representing 0.90% of
all inpatient stays. Having no direct knowledge of the
costs involved in the treatment of these patients, and
using their ambulatory price for DRG as a proxy, we
may state that, to the hospitals, these stays imply an
expenditure that amounts to € 1,109,903.98, for which
they will not be reimbursed.
The prevalence of these cases varied from hospital to
hospital, ranging from 0.10% to 2.40% of the total of
inpatients (as shown in table 1). The registry of these
stays as outpatient visits, assuming all patients were cov-
ered by the National Health Service, would allow hospi-
tals to receive further funding of € 878,875.57. In
individual hospitals, that funding would represent from
0.04% up to 3.85% of the allotted budget for ambulatory
cases classified by DRG.
The differences between hospitals are not explained by
the type of hospital, as defined by the Central Adminis-
tration of the Health System for funding purposes. Hos-
pitals M and A, for instance, belong to the same
economic group but show clearly different admission
policies. In hospital M, the proportional gain of reconsi-
dering these admissions is just 0.19%, corresponding to
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represent 3.85%, corresponding to € 97,547.03.
Conclusions
This short paper demonstrates that a proper manage-
ment of patient admission may increase hospital fund-
ing. Invalid inpatient stays result in no kind of
reimbursement for the hospital. The timely detection of
these cases, and the changing of their registry to outpa-
tient visits, would allow the hospital to seek reimburse-
ment for the costs it has incurred with these patients.
Author details
1Serviço de Bioestatística e Informática Médica, Faculdade de Medicina da
Universidade do Porto, Porto, Portugal.
2CINTESIS - Center for Research on
Health Technologies and Information Systems, Porto, Portugal.
Published: 6 October 2010
doi:10.1186/1472-6963-10-S2-A13
Cite this article as: Lema et al.: Invalid inpatient stays and their
potential reimbursement. BMC Health Services Research 2010 10(Suppl 2):
A13.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Table 1 Invalid Inpatients (length of stay under 24 hours), 2008
Hospitals N % Reimbursable Value Not-NHS Reimbursable Value NHS Weight on Budget (NHS)
A 263 1.10 € 135,776.17 € 97,547.03 3.85%
B 611 2.40 € 251,163.42 € 177,136.62 3.77%
C 447 1.50 € 179,499.43 € 185,296.26 2.73%
D 93 0.60 € 21,927.06 € 13,187.26 2.28%
E 349 1.40 € 155,451.66 € 114,649.19 1.64%
F 27 0.30 € 6,593.53 € 11,291.34 0.78%
G 478 1.40 € 124,546.82 € 122,639.12 0.75%
H 107 0.70 € 42,635.22 € 23,017.46 0.69%
I 193 0.90 € 39,721.42 € 30,214.05 0.48%
J 12 0.70 € 4,525.08 € 2,917.73 0.32%
K 18 0.10 € 13,561.40 € 8,598.14 0.27%
L 64 0.30 € 8,090.17 € 9,129.82 0.20%
M 99 0.20 € 46,775.88 € 41,266.54 0.19%
N 34 0.70 € 4,070.98 € 1,913.86 0.17%
O 100 0.90 € 67,770.03 € 33,047.41 0.09%
P 12 0.10 € 7,895.70 € 6,969.74 0.04%
Total 2,907 0.90 € 1,109,903.98 € 878,875.57 0.66%
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